Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bemnifosbuvir-Ruzasvir · 2 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| Bemnifosbuvir - Ruzasvir (BEM/RZR) | EXPERIMENTAL | - |
| Sofosbuvir-Velpatasvir (SOF/VEL) | ACTIVE_COMPARATOR | - |
| Bemnifosbuvir-Ruzasvir (BEM/RZR) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Bemnifosbuvir-Ruzasvir | DRUG | BEM/RZR Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 8 weeks (in those without cirrhosis) or 12 weeks (in those with compensated cirrhosis) |
| Sofosbuvir-Velpatasvir | DRUG | SOF/VEL Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 12 weeks |
| Bemnifosbuvir-Ruzasvir (BEM/RZR) | DRUG | BEM/RZR Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 8 weeks (in those without cirrhosis) or 12 weeks (in those with compensated cirrhosis) |
| Sofosbuvir-Velpatasvir (SOF/VEL) | DRUG | SOF/VEL Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 12 weeks |
Key Inclusion Criteria: * Use of adequate contraception for females of childbearing potential * Must be direct-acting antiviral (DAA)-treatment-naïve (never exposed to an approved or experimental DAA for HCV) * Documented medical history compatible with chronic HCV * Either no liver cirrhosis or wi...
Bemnifosbuvir-Ruzasvir is an investigational oral treatment being developed for chronic hepatitis C virus infection. It is a fixed-dose combination of two small molecule antivirals studied in adults aged 18 years and older. It has not been approved by the FDA and remains in Phase 3 clinical development.
Bemnifosbuvir-Ruzasvir targets the hepatitis C virus. The combination pairs bemnifosbuvir, a nucleotide prodrug, with ruzasvir, an NS5A inhibitor, so the two components act on distinct HCV viral proteins. This dual mechanism is intended to suppress viral replication across HCV genotypes.
Bemnifosbuvir-Ruzasvir is being developed by Atea Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker AVIR. Atea is running the Phase 3 program for the combination in chronic hepatitis C virus infection.
Bemnifosbuvir-Ruzasvir is in Phase 3 development. Two Phase 3 trials are active and none have been completed. The drug is investigational and has not received FDA approval for chronic hepatitis C virus infection.
Bemnifosbuvir-Ruzasvir is being studied in two active Phase 3 trials, both comparing BEM/RZR with sofosbuvir/velpatasvir in adults with chronic HCV. NCT07037277, called C-Forward, enrolls 880 patients across Europe, Asia, Africa and the Middle East. NCT06868264, called C-BEYOND, enrolls 880 patients in the United States and Canada. Both are active and not recruiting.